Forte Biosciences, Inc.
FBRXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Forte Biosciences, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Forte Biosciences, Inc. — 10-K filed Feb 27, 2020
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 10 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 17, 2026. The latest institutional report shown is dated Jun 30, 2024; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| REAP Financial Group, LLC | 2024-06-30 | 97 | Not shown | SEC filing |
| BML Capital Management, LLC | 2024-06-30 | 1,761,702 | Not shown | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2024-06-30 | 346,292 | Not shown | SEC filing |
| HSBC HOLDINGS PLC | 2024-06-30 | 10,745 | Not shown | SEC filing |
| VANGUARD GROUP INC | 2024-06-30 | 665,230 | Not shown | SEC filing |
| NORTHERN TRUST CORP | 2024-06-30 | 26,817 | Not shown | SEC filing |
| MORGAN STANLEY | 2024-06-30 | 3,804 | Not shown | SEC filing |
| OSAIC HOLDINGS, INC. | 2024-06-30 | 1,080 | Not shown | SEC filing |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | 2024-06-30 | 193 | Not shown | SEC filing |
| Qube Research & Technologies Ltd | 2024-06-30 | 3 | Not shown | SEC filing |
| RENAISSANCE TECHNOLOGIES LLC | 2024-06-30 | 133,400 | Not shown | SEC filing |
| ADAR1 Capital Management, LLC | 2024-06-30 | 159,258 | Not shown | SEC filing |
| FARALLON CAPITAL MANAGEMENT LLC | 2024-06-30 | 1,810,455 | Not shown | SEC filing |
| Royal Bank of Canada | 2024-06-30 | 137 | Not shown | SEC filing |
| FMR LLC | 2024-06-30 | 128 | Not shown | SEC filing |
| MORGAN STANLEY | 2024-06-30 | 3,804 | Not shown | SEC filing |
| GOLDMAN SACHS GROUP INC | 2024-06-30 | 20,776 | Not shown | SEC filing |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2024-06-30 | 34,344 | Not shown | SEC filing |
| BVF INC/IL | 2024-06-30 | 2,982,105 | Not shown | SEC filing |
| UBS Group AG | 2024-06-30 | 24,310 | Not shown | SEC filing |
- Each value is checked against Forte Biosciences, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 20 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- PERCEPTIVE ADVISORS LLC: 3,265,359 shares reported 2024-03-31; 3,265,359 shares reported 2024-06-30.
- REAP Financial Group, LLC: 97 shares reported 2024-03-31; 97 shares reported 2024-06-30.
- JPMORGAN CHASE & CO: 17 shares reported 2023-12-31; 17 shares reported 2024-03-31.
- REAP Financial Group, LLC: 97 shares reported 2023-12-31; 97 shares reported 2024-03-31.
31 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Forte Biosciences, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2020-04-14 · Oliveira Steven Michael: Larger than 25 of the 26 other insider purchases of Common Stock on file. SEC filing
- 2020-03-02 · Oliveira Steven Michael: Larger than 24 of the 26 other insider purchases of Common Stock on file. SEC filing
- 2017-04-19 · Hasnain Faheem: Larger than all 26 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2020-06-25–2020-06-29: 3 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing )
- 2019-05-24–2019-05-30: 6 event(s) across 4 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-12-30 | Riley Antony A · CHIEF FINANCIAL OFFICER | Common Stock | P — Open market or private purchase | +9,680 | 26.33 | SEC filing |
| 2024-11-21 | Riley Antony A · CHIEF FINANCIAL OFFICER | Common Stock | P — Open market or private purchase | +22,514 | 5.55 | SEC filing |
| 2023-12-18 | Wagner Paul A. · See Remarks | Common Stock | P — Open market or private purchase | +10,000 | 0.75 | SEC filing |
| 2023-12-14 | Wagner Paul A. · See Remarks | Common Stock | P — Open market or private purchase | +10,000 | 0.72 | SEC filing |
| 2023-12-13 | Wagner Paul A. · See Remarks | Common Stock | P — Open market or private purchase | +10,520 | 0.70 | SEC filing |
| 2023-12-12 | Wagner Paul A. · See Remarks | Common Stock | P — Open market or private purchase | +4,776 | 0.65 | SEC filing |
| 2023-12-11 | Wagner Paul A. · See Remarks | Common Stock | P — Open market or private purchase | +25,000 | 0.65 | SEC filing |
| 2023-12-08 | Wagner Paul A. · See Remarks | Common Stock | P — Open market or private purchase | +15,000 | 0.62 | SEC filing |
Showing 8 of 13 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-16 | Riley Antony A · CHIEF FINANCIAL OFFICER | Stock Option (right to buy) | A — Grant, award, or other acquisition | +22,000 | SEC filing |
| 2026-06-16 | Wagner Paul A. · SEE REMARKS | Stock Option (right to buy) | A — Grant, award, or other acquisition | +500,000 | SEC filing |
| 2026-05-29 | Doberstein Stephen K · Director | Restricted Stock Units | A — Grant, award, or other acquisition | +18,353 | SEC filing |
| 2026-05-29 | GRYSKA DAVID W · Director | Restricted Stock Units | A — Grant, award, or other acquisition | +18,353 | SEC filing |
| 2026-05-29 | Brun Scott C. · Director | Restricted Stock Units | A — Grant, award, or other acquisition | +18,353 | SEC filing |
| 2026-05-29 | VINCENT RICHARD G · Director | Restricted Stock Units | A — Grant, award, or other acquisition | +18,353 | SEC filing |
| 2026-05-29 | Kornfeld Steven · Director | Restricted Stock Units | A — Grant, award, or other acquisition | +18,353 | SEC filing |
| 2026-05-29 | Kapoor Shivpreet Singh · Director | Restricted Stock Units | A — Grant, award, or other acquisition | +18,353 | SEC filing |
Showing 8 of 30 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2022-05-12 | Wagner Paul A. · See Remarks | Stock Option (right to buy) | D — Disposition to the issuer | −40,000 | SEC filing |
| 2017-12-08 | Jolly Douglas · EVP, Research & Pharm Devel | Common Stock | J — Other acquisition or disposition | +739 | SEC filing |
| 2017-12-08 | Duvall Martin J · Chief Executive Officer | Common Stock | J — Other acquisition or disposition | +2,500 | SEC filing |
| 2017-12-08 | FOLETTA MARK G · EVP & Chief Financial Officer | Common Stock | J — Other acquisition or disposition | +2,500 | SEC filing |
| 2017-12-08 | GRUBER HARRY E · President, Research & Devel | Common Stock | J — Other acquisition or disposition | +2,500 | SEC filing |
| 2017-12-08 | Das Asha · SVP & Chief Medical Officer | Common Stock | J — Other acquisition or disposition | +2,500 | SEC filing |
| 2017-04-19 | BERGER FRANKLIN M · Director | Common Stock | J — Other acquisition or disposition | +25,335 | SEC filing |
Showing 7 of 7 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.